Table 2.
Patient demographics of patients in the three endotypes.
| Clinical Variables | Resolved (12) | Suppressive (7) | Unresolved (5) | P-value |
|---|---|---|---|---|
| Age | 60.5 ± 13.7 (12) | 53.7 ± 13.6 (7) | 56.8 ± 6.1 (5) | 0.535 |
| Sex (Male) | 75.0% (9/12) | 71.4% (5/7) | 60.0% (3/5) | 0.850 |
| Body Mass Index | 33.2 ± 6.9 (10) | 29.3 ± 3.2 (4) | 23.9 ± 2 (5) | 0.010 |
| Admitted to ICU (Yes) | 33.3% (4/12) | 28.6% (2/7) | 20.0% (1/5) | 1.000 |
| Hospitalized Duration (Days) | 18.2 ± 14.8 (12) | 15 ± 17.9 (7) | 10.8 ± 7.6 (5) | 0.381 |
| Post-COVID Symptoms (Yes) | 16.7% (2/12) | 85.7% (6/7) | 40.0% (2/5) | 0.015 |
| Discharge to Follow-up (Days) | 54.1 ± 14.2 (12) | 45.7 ± 10 (7) | 46.8 ± 20.4 (5) | 0.395 |
| Smoker (Yes) | 20.0% (2/10) | 0.0% (0/5) | 25.0% (1/4) | 0.561 |
| Worst Laboratory Values | ||||
| Highest %Neutrophil | 0.8 ± 0.1 (12) | 0.7 ± 0.1 (7) | 0.8 ± 0.1 (5) | 0.091 |
| Lowest %Lymphocyte | 0.1 ± 0 (12) | 0.1 ± 0 (7) | 0.1 ± 0 (5) | 0.217 |
| Highest %Monocyte | 0.1 ± 0 (12) | 0.1 ± 0 (7) | 0.1 ± 0 (5) | 0.276 |
| Lowest Platelets (103/µL) | 253 ± 122 (12) | 183 ± 61 (7) | 278 ± 128 (5) | 0.245 |
| Highest Creatinine | 85.1 ± 42.3 (12) | 63.9 ± 9.8 (7) | 171± 192 (5) | 0.034 |
| Highest Estimated SOFA Score | 3.7 ± 2.8 (12) | 2.9 ± 2.9 (7) | 4.6 ± 3.1 (5) | 0.273 |
| Highest WHO COVID-19 Score | 5.8 ± 1.4 (12) | 5.6 ± 1.6 (7) | 6.0 ± 1.2 (5) | 0.617 |
| Treatments During Hospitalization | ||||
| Antifungal (Yes) | 8.3% (1/12) | 14.3% (1/7) | 0.0% (0/5) | 1.000 |
| Antibiotics (Yes) | 83.3% (10/12) | 71.4% (5/7) | 80.0% (4/5) | 0.819 |
| Antiviral | ||||
| Lopinavir/Ritonavir (Yes) | 33.3% (4/12) | 0.0% (0/7) | 0.0% (0/5) | 0.144 |
| Remdesivir (Yes) | 0.0% (0/12) | 28.6% (2/7) | 0.0% (0/5) | 0.112 |
| Other Antiviral (Yes) | 8.3% (1/12) | 0.0% (0/7) | 20.0% (1/5) | 0.457 |
| Immunomodulator | ||||
| Systemic Corticosteroids (Yes) | 41.7% (5/12) | 85.7% (6/7) | 100.0% (5/5) | 0.038 |
| Tocilizumab (Yes) | 0.0% (0/12) | 14.3% (1/7) | 40.0% (2/5) | 0.057 |
| Sarilumab (Yes) | 8.3% (1/12) | 0.0% (0/7) | 0.0% (0/5) | 1.000 |
| Other Immunomodulator (Yes) | 16.7% (2/12) | 0.0% (0/7) | 20.0% (1/5) | 0.564 |
| Other Treatments | ||||
| Vasopressor support (Yes) | 8.3% (1/12) | 14.3% (1/7) | 0.0% (0/5) | 1.000 |
| Prone Positioning (Yes) | 25.0% (3/12) | 28.6% (2/7) | 0.0% (0/5) | 0.656 |
| Inhaled Nitric Oxide (Yes) | 0.0% (0/12) | 28.6% (2/7) | 0.0% (0/5) | 0.112 |
| Blood Transfusion (Yes) | 8.3% (1/12) | 0.0% (0/7) | 0.0% (0/5) | 1.000 |
For categorical variables, significance was tested using the Chi-squared test with Yates’s correction, or the exact Fisher test if any expected value was <5, and the percentage and fraction of patients fitting the category is displayed. For continuous variables, the Kruskal-Wallis test was used, and the mean ± standard deviation of the variable is displayed, with the number of patients assessed in brackets. Significant p-values (p <0.05) are bolded, indicating the metadata variable significantly differs across the three endotypes. Non-significant differences in comorbidities, symptoms, and follow-up metrics are in Table S3 .